With President Donald Trump renewing his campaign focus on lowering drug costs, many are wondering if blockbuster medications like Ozempic could soon face pricing pressure. As Ozempic continues to dominate headlines for its weight loss and diabetes benefits — and with prices soaring in the U.S. compared to other countries — public demand for affordability is at an all-time high.
Trump’s History with Big Pharma
During his first term, Trump frequently criticized pharmaceutical companies for “ripping off” Americans and even signed executive orders aimed at importing cheaper drugs and tying U.S. prices to international rates. While those policies faced legal and political hurdles, they reflected a populist desire to take on Big Pharma’s pricing power.
Now, as Trump re-enters the political spotlight, his team is signaling a return to that rhetoric — possibly targeting high-profile drugs like Ozempic.
Why Ozempic?
- Ozempic, made by Novo Nordisk, has become one of the most in-demand medications in the U.S., used not just for Type 2 diabetes but also off-label for weight loss.
- U.S. patients often pay hundreds of dollars per month, while the same drug costs significantly less in Europe and Canada.
- This pricing gap could make Ozempic a prime target for campaign promises focused on healthcare reform.
What Could Happen?
- Trump could propose importation of cheaper alternatives, encourage Medicare price negotiations, or demand greater transparency on pricing.
- However, without bipartisan support or changes in legislation, actual price reductions would be difficult to enforce.
Conclusion
While Trump may not have the authority today to force Ozempic prices down, his platform could increase public pressure on drugmakers and reignite the battle over pharmaceutical costs. Whether real action follows remains to be seen — but Ozempic is now on the political radar.
